#hirawats

[hirawatsuniforms]

Some weekend motivation by @dr.rutuja_house_of_smiles in our lab coat to fill your exhausted self with some much needed energy!

[scrubs, india, indian doctors, doctor scrubs, medical scrubs, med student life, indian doctors, indian doctor, doctor life]

[playermagic23]

EXCLUSIVE: Sanjay Puran Singh Chauhan will direct Akshay Kumar's Tirangaa, which is slated to go on floors by the end of 2024.

Last month, Bollywood Hungama exclusively reported that Akshay Kumar's Tirangaa is not a replica of the same-titled 1993 film starring Nana Patekar and Raaj Kumar. Bollywood Hungama has reported that the film will be directed by Sanjay Puran Singh Chauhan.

According to a source, "The film's producers - Ashvin Varde, Subhash Kale, and Narendra Hirawat - along with Akshay Kumar realized that Sanjay Puran Singh Chauhan would be an appropriate candidate to handle a picture like this and give it the essential commercial approach. This is how the renowned director came on board."

According to the source, "Tirangaa is expected to go on floors by December 2024."

Sanjay Puran Singh Chauhan previously directed the films Lahore (2010) and 72 Hoorain (2023), both of which won national awards. He was also one of the authors for Ranveer Singh's cricket drama '83 (2021).

Sanjay and Akshay were close to working together on a film called Gorkha. It was to be produced by Aanand L Rai, but after the announcement, it was abandoned. In January 2023, Aanand L Rai told Bollywood Hungama, "Yes, that is correct. We are not making this film right now. There are technical issues. There are factual clarifications that must be made.

Sanjay Puran Singh Chauhan also planned to develop Chandamama Door Ke, a space film starring the late Sushant Singh Rajput.

On August 10, Narendra Hirawat denied that Tirangaa is a remake of the original film of the same name. He told Bollywood Hungama, "In recent days, there have been a few media stories suggesting that we are creating a remake of the film Tirangaa with Shri Akshay Kumar in the lead. We would want to state unequivocally that this report is false. Yes, we are creating a film with Shri Akshay Kumar in the lead, however we want to make it clear that it is NOT a remake of any film. It's a whole new and original script. An official announcement about this will be made soon."

[telugutimesdigimedia]

American company invests Rs.800 crores in Telangana

The Telangana government has entered into an MoU with Bristol Meyers, an American pharma company. The agreement was signed by the representatives of the Bristol Mayors organization under the leadership of the Minister of State for IT and Industries KTR. The minister said that 1500 people will get employment opportunities through this company which has come forward with an investment of more than Rs.800 crores. On this occasion, Bristol Mayors explained to the representatives of the organization that the world's largest pharma cluster is being established in Hyderabad.

[parveenbabimemories1]

Directed byManmohan Desai

Written by Kader Khan (dialogue)

K. K. Shukla (scenario)

Screenplay by Prayag Raj Sharma

Story by Jeevanprabha M. Desai

Pushpa Sharma (story idea)

Produced by Manmohan Desai

Starring Vinod Khanna, Rishi Kapoor, Amitabh Bachchan, Neetu Singh, Parveen Babi, Shabana Azmi, Nirupa Roy,Pran

CinematographyPeter Pereira

Edited by Kamlakar Karkhanis

Music by Laxmikant–Pyarelal

Anand Bakshi (lyrics)Distributed by Hirawat Jain & Co.

Release date 27 May 1977

Leena Daru wardrobe

Kamal choreographer

Playback singers Mohammed Rafi, Kishore Kumar, Lata Mangeshkar, Mahendra Kapoor, Shailendra Singh, Mukesh

Did you know

When the movie released it was a huge hit in West Indies

The film made Amitabh a superstar god in the Caribean Islands. Trinidad, Tobago, Guyana and several other countries played Amar Akbar Anthony in the theaters. The film was house full for months,where getting a ticket was impossible. It was not just Indians, but millions of non Indians who fell in love with the film and embraced "Anthony" as their new Indian hero.

[xtruss]

Food and Drug Administration (FDA) Approves the First New Schizophrenia Drug in Decades

— By Alice Park | September 27, 2024

Steve Belkowitz (Bristol Myers Squibb)

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on September 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric disorder.

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely different way from existing medications for schizophrenia, which is building excitement and enthusiasm among doctors and patients alike.

How Scientists Developed The New Drug

While schizophrenia treatments primarily target the dopamine neurotransmitter system in the brain, Cobenfy goes after a different one, the cholinergic system, through muscarinic receptors. Decades ago, scientists at Eli Lilly had studied the muscarinic system as a possible treatment for Alzheimer’s disease, since manipulating it seemed to reduce some of the symptoms of Alzheimer’s-related psychosis that some patients develop. The company's researchers also serendipitously learned that a compound they developed to activate the system also improved symptoms of schizophrenia. But cells in many parts of the body—the brain, but also the bladder, gut, salivary glands, eyes, and heart—contain receptors for the muscarinic system, which meant it was challenging to selectively target just those in the brain and not elsewhere. Because the compound, called xanomeline, caused wide-ranging side effects, Lilly's researchers shelved further study on it.

Andrew Miller, co-founder of Karuna, became intrigued by this research and tried to figure out how to activate the muscarinic system in the brain while tamping it down elsewhere in the body. He and his team tested 7,000 compounds and eventually combined xanomeline with a drug that had been approved by the FDA in the 1970s for treating overactive bladder, to suppress muscarinic activity elsewhere in the body. "It's a pretty out-of-the-box approach," says Miller. The overactive bladder drug "has nothing to do with psychiatry," he said. Combining it with a serendipitous discovery of xanomeline "didn't fit the traditional model of innovative drug discovery." But it worked.

What Studies Have Found

In a study the company published last December in the journal Lancet, the researchers reported that the combination—now called Cobenfy but then called KarXT—helped to significantly reduce symptoms of schizophrenia such as hallucinations, delusions, paranoia, social withdrawal, and a loss of motivation compared to a placebo. Those data were part of the application that the company submitted to the FDA for approval.

Bristol Myers Squibb acquired Karuna in 2023 largely based on these encouraging results. “When we looked at the available neuroscience and neuropsychiatric assets out there, we didn’t want the next dopamine agonist or antagonist in the marketplace, which all of the physicians have [already] seen,” says Adam Lenkowsky, chief commercialization officer for Bristol Myers Squibb. “We wanted a truly revolutionary asset, one with a different mechanism: a first-in-class, best-in-category asset we think could transform the space.”

Samit Hirawat, chief medical officer at Bristol Myers Squibb, says that not only does Cobenfy address schizophrenia in an entirely new way, but its approach could be used for other neurological conditions as well. "The breadth of applicability of this medicine is what attracted us.”

Dr. Rishi Kakar, chief scientific officer at Segal Trials who led several studies on Cobenfy, says that “the uniqueness of the mechanism of action differentiated this medication from everything else we had so far, and truly caught my eye right off the bat.” Kakar—a psychiatrist who treats patients as well as conducts research—says that historically, only about 40% of people with schizophrenia respond to dopamine-based treatments, and the other 60% who may respond often stop taking their medications because of intolerable side effects, which can include uncontrolled muscle movements, dizziness, fainting, and weight gain.

The trials included patients who were hospitalized for acute schizophrenia and randomly assigned to receive Cobenfy—as a pill taken twice a day—or a placebo for five weeks. In order to reflect the real-world population of patients, some had been taking existing medications but stopped because of the side effects, or weren’t compliant. All patients went through a wash-out period of up to two weeks to ensure any measurements of their outcomes during the study were due solely to Cobenfy or placebo. Patients received escalating doses of the drug, and prescribing doctors were able to adjust dosages for their patients depending on their symptoms.

The studies documented a significant reduction in overall symptoms of schizophrenia in the patients receiving Cobenfy compared to placebo. “My viewpoint is that [this difference] can mean someone can potentially carry on a better life by having symptom control,” says Kakar.

What Else To Know About Cobenfy

The FDA approved Cobenfy as a monotherapy—meaning it is meant to be taken alone, without other medications—but more studies will be needed to see how the medication works in combination with existing treatments, and what the benefits and risks are of combining them. “I think many clinicians are going to try this as a first-time pharmacological option, because they will find that the reduction in symptoms is fairly robust,” says Kakar. “From what I saw, it has true value for the unmet need we have.” Lenkowsky says Bristol Myers Squibb is conducting a trial studying Cobenfy in combination with dopamine-based medications that will yield results in about a year.

In contrast to the existing dopamine-based treatments, the side effects of Cobenfy reported by the volunteers in the studies were mostly mild to moderate, involving nausea and gastrointestinal distress, and tended to lessen with time. The label also alerts patients that the drug is associated with urinary retention, increased heart rate and swelling in the face in rare cases; the medication is not recommended for people with a history of liver or kidney disorders.

Bristol Myers Squibb is continuing to study the drug for its longer term effects, as well as to understand and potentially guide doctors on how to adjust doses for patients as their symptoms change over time. The success in schizophrenia patients may lead to other uses of the drug in other conditions as well. “Neuropsychiatry is at the cusp of bringing an explosion of new medicines, and Cobenfy is the start of a pipeline of potential products,” says Hirawat. The company is currently studying the drug in Alzheimer’s-related psychosis, and next year plans to start late-stage trials investigating whether it can improve bipolar mania, Alzheimer’s-associated agitation, and Alzheimer’s-associated cognitive impairment. In 2027, the company hopes to begin trials in people with autism.

How Much Will Cobenfy Cost?

According to a Bristol Myers Squibb spokesperson, the wholesale cost for a month's supply will be $1,850. Depending on people's insurance coverage, that cost could be lower for individual patients. Bristol Myers Squibb estimates that 80% of people with schizophrenia in the U.S. have insurance coverage either through Medicare or Medicaid.

[starfriday]

Makers of Auron Mein Kahan Dum Tha Unveil New Video of Ae Dil Zara with Exclusive Visuals*

After the success of the lyrical videos, the makers of Auron Mein Kahan Dum Tha are set to release an exclusive visual for the song Ae Dil Zara. This track captures the emotions of lovers.

The song has deeply resonated with the cast, particularly Ajay Devgn and Tabu.

Beautifully sung by Sunidhi Chauhan and Jubin Nautiyal, the song features music composed by M. M. Keeravani, with heartfelt lyrics by Manoj Muntashir. The lyrical videos have already garnered immense popularity, prompting the release of this exclusive visual.

Auron Mein Kahan Dum Tha unfolds as an epic love story, tracing the journey of Krishna and Vasudha through numerous challenges, including Krishna's imprisonment. Them meeting after 22 years explores the endurance of their love amidst adversity.

Presented by NH Studioz and produced by Narendra Hirawat, Kumar Mangat Pathak (Panorama Studios), Sangeeta Ahir, and Shital Bhatia, Auron Mein Kahan Dum Tha is slated for theatrical release on 2nd August 2024.

[cuzyanavi]

Амар, Акбар, Антони - Боевик, комедия, драма Индия 1977 Парвин Баби, Амитабх Баччан, Риши Капур

Ha бедную семью обрушились несчастья. Отец вынужден убегать от бандитов, мать ослепла от болезни и горя. А трое маленьких детей потерялись. У каждого из них судьба сложилась по-разному. Трое юношей встретились, еще не зная, что они братья. В конце концов, семья соединилась - нашлись отец, мать и все трое братьев.

#боевик #комедия #драма #болливуд

Выпущено: Индия, Hirawat Jain and Company, M.K.D. Films Combine Режиссер: Манмохан Десаи В ролях: Амитабх Баччан, Риши Капур, Винод Кханна, Ниту Сингх, Парвин Баби, Шабана Азми, Нирупа Рой, Пран, Дживан, Юсуф, Насир Хуссейн, Камал Капур, Хелен, Надира, Ранджит

[best2daynews]

Ajay Devgn, Tabu to be seen in new film ‘Auron Mein Kahan Dum Tha’ - today news

New Delhi: Actors Ajay Devgn and Tabu will be seen in a new film titled Auron Mein Kahan Dum Tha to be directed by Neeraj Pandey, known for A Wednesday, Special 26 and Baby. It will also feature Jimmy Shergill. The film is produced by Shital Bhatia, Narendra Hirawat, Reliance Entertainment and Kumar Mangat Pathak. Devgn began his professional career with Phool Aur Kaante in 1991 and over time,…

[adarshswaroop]

AJAY DEVGN - TABU STAR IN NEERAJ PANDEY DIRECTORIAL… Director #NeerajPandey - known for films like #AWednesday, #Special26, #Baby and #MSDhoni - directs #AuronMeinKahanDumTha… Shoot commenced on Sat with the lead cast along with #JimmyShergill. #AuronMeinKahanDumTha is produced by Shital Bhatia, Narendra Hirawat, Reliance Entertainment and Kumar Mangat Pathak… Music by #MMKreem… The musical-love story is set between 2002 and 2023. https://www.instagram.com/p/CoUWU2oJm0e/?igshid=NGJjMDIxMWI=

[decentralvaccine]

Promising Data On mRNA Cancer Vaccines

Moderna and BioNTech recently reported positive early clinical data for their mRNA cancer vaccines in partnership with PD-1/L1 inhibitors. But as over a decade of research has failed to transpire into approved therapies, several biopharma executives remain on the fence about the future for cancer vaccines, while others believe the field is getting closer to finding its sweet spot.

“These are good data that we have to look at and see and understand,” Bristol Myers Squibb Chief Medical Officer Samit Hirawat, M.D., said in an interview on the sidelines of the J.P. Morgan Healthcare Conference earlier this month.

[hirawatsuniforms]

Our scrubs are loved by more than 1 LAKH of you because they are so pocket friendly, durable and comfortable! Order your first pair now and get 10% OFF 🫶🏻

(Or use code FAVE to get a special discount✨)

[scrubs, india, indian doctors, doctor scrubs, medical scrubs, med student life, indian doctors, indian doctor, doctor life]

#hirawats #doctors #doctorsindia #doctormemes #internmemes #doctorlifestyle #medico #medicalstudent #medicalstudents

#medicalstudentlife #medstudent #medstudents

[amitbchoudhury]

Enerzal’s campaign delves into uncertainty and battle during lockdown – ET BrandEquity Produced and launched by SoCheers Films, this home shot video delves into the uncertainty and battle each human being is possibly facing during this pandemic.

[bubblesandknife]

On the seashore, you might have noticed how the tides just erase all the imprints of people's foot. No matter how deep it has been etched, the waves gently erase them away.

Few people in my life have played the very exact role of those tides and waves. You might have met one. They just appear in your life from nowhere and gently sweep away all those scabs with themselves. They make you meet your own self with a very different perspective and make you realize how ecstatic life can be regardless of the numerous flaws you own.

But then a time comes too when those waves have to go away. I know tides, as usual, come back and meet the seashore but in my voyage, they have waved me an ultimate goodbye with a deep imprint on my heart which I'll never allow any other ripple to sweep it away.

- Nandini Hirawat

@bubblesandknife

#poem #love #sadness #tumblr #trending #quotes #ootd

[starfriday]

*Auron Mein Kahan Dum Tha Makers Unveil the Teaser of New Song "Jahan Se Chale The"*

View this post on Instagram

A post shared by Ajay Devgn (@ajaydevgn)

Auron Mein Kahan Dum Tha has been the talk of the town since its announcement, whether for its enchanting music composed by Oscar-winning M.M. Kreem or the intrigue that the trailer has built.

In a recent development, the makers have released a teaser for the upcoming song Jahan Se Chale The, featuring a jail scene from the movie. In this teaser, we see Krishna, played by Ajay, yearning to meet Vasu.

Sung by the talented Sunidhi Chauhan and Jubin Nautiyal, Jahan Se Chale The is set to be a treat for music lovers.

Presented by NH Studioz, Auron Mein Kahan Dum Tha is a Friday Filmworks Production, produced by Narendra Hirawat, Kumar Mangat Pathak (Panorama Studios), Sangeeta Ahir, and Shital Bhatia. The film is set for a theatrical release on 2nd August 2024.